Importance Concerns about the cardiovascular safety of recombinant human growth
hormone (rhGH) treatment in childhood have recently been raised; however, long-term …

Growth hormone (GH) therapy dates back to 1958 and, though has shown an excellent
safety profile in the short-term, has never ceased to raise concern about potential long-term …

Background An increasing body of evidence supports the view that both an adverse
intrauterine milieu and rapid postnatal weight gain in children born small for gestational age …

Background Childhood growth hormone treatment has been associated with increased
cardiovascular mortality and morbidity in adults born small for gestational age (SGA) …

Context Long‐term safety of growth hormone (GH) treatment is an area of much debate.
Studies including children treated with GH not only due to GHD, but also due to non‐GHD …

Context Growth hormone (GH) treatment has a generally good safety profile; however,
concerns about increased mortality risk in adulthood have been raised. Objective This work …

The use of recombinant human growth hormone (rhGH) in children and adolescents has
expanded since its initial approval to treat patients with severe GH deficiency (GHD) in 1985 …

Objectives Preliminary data from the French cohort of the Safety and Appropriateness of
Growth hormone treatments in Europe (SAG hE) study raised concerns regarding the safety …

Context: Previously we showed that pubertal children born small for gestational age (SGA)
with a poor adult height (AH) expectation can benefit from treatment with GH 1 mg/m2 per …

Abstract Background: Between 1985 and 2006, the National Cooperative Growth Study
(NCGS) monitored the safety and efficacy of recombinant human growth hormone (rhGH) in …